Kymera IPO Presentation Deck
CANCER
FIBROSIS
Liquid Tumors
o pro
Autoimmune
Fibrosis
#
Full and Durable Regressions Across Multiple
in vivo Preclinical Tumor Models
Mice bearing STAT3-dependent
ALK+ ALCL SU-DHL-1 (above) and
STAT3-driven ALK+ ALCL xenograft
model SUP-M2 (below) tumors
dosed with STAT3 degrader
Dose and degradation dependent
tumor growth inhibition observed
with once a week IV dosing
30 mg/kg sufficient to drive full
tumor regression that was durable
for multiple weeks after the last
dose
KYMERA ©2020 KYMERA THERAPEUTICS, INC.
Tumor Volume (mm²)
Tumor Volume (mm³)
2000
1000
2000-
1000
10
Days
Days
STAT3 Degrader 5 mg/kg. QW
→STAT3 Degrader 10 mg/kg, QW
→STAT3 Degrader 25 mg/kg. QW
STAT3 Degrader 50 mg/kg. QW
Vehicle
STAT3 Degrader 30 mg/kg, QWView entire presentation